The project team conducted an extensive review and summary of neutropenia literature, guidelines, and meta-analyses and reviewed current National Institutes of Health-and ONS-funded studies. The panel of experts was invited to participate in a two-day symposium held in January 2006 in Pittsburgh, PA, during which they presented their respective areas of expertise to the project team (see inset). The expert presentations were recorded and transcribed for use in the preparation of this article. Data Synthesis: A comprehensive review of current literature regarding CIN risk assessment, practice guidelines, management, impact on dose-dense and dose-intense cancer treatment, complications, costs related to hospitalizations, and treatment strategies has been compiled.
Conclusions: CIN is the most common dose-limiting toxicity of cancer therapy. Medical practice guidelines and risk assessment models for appropriate use of myeloid growth factors and management of febrile neutropenia have been developed to assess patients for CIN complications prechemotherapy and during CIN episodes. CIN affects patients, families, practitioners, and the healthcare system. Although much is known about this common chemotherapy complication, a great deal remains to be learned. Implications for Nursing: CIN is a serious and global problem in patients receiving cancer therapy. Oncology nurses need to critically analyze their own practices when assessing, managing, and educating patients and families about CIN. This material is protected by U.S. copyright law. Unauthorized reproduction is prohibited. To purchase quantity reprints, please e-mail reprints@ons.org or to request permission to reproduce multiple copies, please e-mail pubpermissions@ons.org.
